{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:15:40Z","timestamp":1793502940844,"version":"4.5.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Beta-blocker and calcium-channel blocker overdoses are associated with severe morbidity and mortality; therefore, it is important to recognize and appropriately treat individuals with toxicity. The most common clinical findings in toxicity are bradycardia and hypotension. In addition to supportive care and cardiac monitoring, specific treatment includes administration of calcium salts, vasopressors, and high-dose insulin euglycaemia treatment. Other advanced treatments (e.g. ECMO) may be indicated depending on the severity of toxicity and specific agents involved.<\/jats:p>","DOI":"10.1093\/ehjacc\/zuad138","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T23:12:32Z","timestamp":1700176352000},"page":"247-253","source":"Crossref","is-referenced-by-count":10,"title":["Beta-blocker and calcium-channel blocker toxicity: current evidence on evaluation and management"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2914-166X","authenticated-orcid":false,"given":"Charlotte E","family":"Goldfine","sequence":"first","affiliation":[{"name":"Division of Medical Toxicology, Department of Emergency Medicine, Mass General Brigham Boston , 75 Francis St , Boson, MA 02115, USA"},{"name":"Harvard Medical School , 25 Shattuck St, Boson, MA 02115 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Troger","sequence":"additional","affiliation":[{"name":"Harvard Medical School , 25 Shattuck St, Boson, MA 02115 , USA"},{"name":"Division of Emergency Medicine, Boston Children\u2019s Hospital , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy B","family":"Erickson","sequence":"additional","affiliation":[{"name":"Division of Medical Toxicology, Department of Emergency Medicine, Mass General Brigham Boston , 75 Francis St , Boson, MA 02115, USA"},{"name":"Harvard Medical School , 25 Shattuck St, Boson, MA 02115 , USA"},{"name":"Department of Global Health and Population, Harvard Humanitarian Institute, Harvard T.H. Chan School of Public Health , Cambridge, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0955-4117","authenticated-orcid":false,"given":"Peter R","family":"Chai","sequence":"additional","affiliation":[{"name":"Division of Medical Toxicology, Department of Emergency Medicine, Mass General Brigham Boston , 75 Francis St , Boson, MA 02115, USA"},{"name":"Harvard Medical School , 25 Shattuck St, Boson, MA 02115 , USA"},{"name":"Department of Psychosocial Oncology and Palliative Care, Dana Farber Cancer Institute , Boston , USA"},{"name":"The Koch Institute for Integrated Cancer Research, Massachusetts Institute of Technology , Cambridge , USA"},{"name":"The Fenway Institute , Boston , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,17]]},"reference":[{"key":"2024021707135134000_zuad138-B1","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1080\/15563650.2021.1989785","article-title":"2020 Annual report of the American Association of Poison Control Centers\u2019 National Poison Data System (NPDS): 38th annual report","volume":"59","author":"Gummin","year":"2021","journal-title":"Clin Toxicol (Phila)"},{"key":"2024021707135134000_zuad138-B2","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/15563650.2022.2131565","article-title":"Vasodilation in patients with calcium channel blocker poisoning treated with high-dose insulin: a comparison of amlodipine versus non-dihydropyridines","volume":"60","author":"Cole","year":"2022","journal-title":"Clin Toxicol (Phila)"},{"key":"2024021707135134000_zuad138-B3","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/15563650.2020.1752918","article-title":"Treatment for beta-blocker poisoning: a systematic review","volume":"58","author":"Rotella","year":"2020","journal-title":"Clin Toxicol (Phila)"},{"key":"2024021707135134000_zuad138-B4","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3109\/15563650.2014.965827","article-title":"Treatment for calcium channel blocker poisoning: a systematic review","volume":"52","author":"St-Onge","year":"2014","journal-title":"Clin Toxicol (Phila)"},{"key":"2024021707135134000_zuad138-B5","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1097\/CCM.0000000000002087","article-title":"Experts consensus recommendations for the management of calcium channel blocker poisoning in adults","volume":"45","author":"St-Onge","year":"2017","journal-title":"Crit Care Med"},{"key":"2024021707135134000_zuad138-B6","volume-title":"Beta-Blocker toxicity","author":"Khalid","year":"2023"},{"key":"2024021707135134000_zuad138-B7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1081\/CLT-100100932","article-title":"Acute Beta blocker overdose: factors associated with the development of cardiovascular morbidity","volume":"38","author":"Love","year":"2000","journal-title":"J Toxicol Clin Toxicol"},{"key":"2024021707135134000_zuad138-B8","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ccc.2021.03.006","article-title":"Cardiovascular drug toxicity","volume":"37","author":"St-Onge","year":"2021","journal-title":"Crit Care Clin"},{"key":"2024021707135134000_zuad138-B9","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1097\/01.CCM.0000278916.04569.23","article-title":"Assessment of hyperglycemia after calcium channel blocker overdoses involving diltiazem or verapamil*","volume":"35","author":"Levine","year":"2007","journal-title":"Crit Care Med"},{"key":"2024021707135134000_zuad138-B10","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1080\/15563650.2020.1725034","article-title":"The unknown known: non-cardiogenic pulmonary edema in amlodipine poisoning, a cohort study","volume":"58","author":"Lindeman","year":"2020","journal-title":"Clin Toxicol"},{"key":"2024021707135134000_zuad138-B11","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1179\/2295333714Y.0000000007","article-title":"Acute respiratory distress syndrome after verapamil intoxication: case report and literature review","volume":"69","author":"Izdes","year":"2014","journal-title":"Acta Clin"},{"key":"2024021707135134000_zuad138-B12","first-page":"8842303","article-title":"Severe noncardiogenic pulmonary edema secondary to massive verapamil overdose and treatment with venovenous extracorporeal membrane oxygenation","volume":"2020","author":"Ho","year":"2020","journal-title":"Case Rep Crit Care"},{"key":"2024021707135134000_zuad138-B13","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/0736-4679(94)90487-1","article-title":"Beta blocker toxicity after overdose: when do symptoms develop in adults?","volume":"12","author":"Love","year":"1994","journal-title":"J Emerg Med"},{"key":"2024021707135134000_zuad138-B14","doi-asserted-by":"crossref","first-page":"bcr2018225324","DOI":"10.1136\/bcr-2018-225324","article-title":"Pharmacological and mechanical management of calcium channel blocker toxicity","volume":"2018","author":"Fadhlillah","year":"2018","journal-title":"BMJ Case Rep"},{"key":"2024021707135134000_zuad138-B15","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1081\/CLT-120023761","article-title":"Glucagon in beta-blocker and calcium channel blocker overdoses: a systematic review","volume":"41","author":"Bailey","year":"2003","journal-title":"J Toxicol Clin Toxicol"},{"key":"2024021707135134000_zuad138-B16","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s13181-020-00758-8","article-title":"Use of a porcine model to evaluate the risks and benefits of vasopressors in propranolol poisoning","volume":"16","author":"Cole","year":"2020","journal-title":"J Med Toxicol"},{"key":"2024021707135134000_zuad138-B17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/15563650.2017.1284329","article-title":"Are vasopressors useful in toxin-induced cardiogenic shock?","volume":"55","author":"Skoog","year":"2017","journal-title":"Clin Toxicol"},{"key":"2024021707135134000_zuad138-B18","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.annemergmed.2013.03.018","article-title":"Critical care management of verapamil and diltiazem overdose with a focus on vasopressors: a 25-year experience at a single center","volume":"62","author":"Levine","year":"2013","journal-title":"Ann Emerg Med"},{"key":"2024021707135134000_zuad138-B19","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2147\/JMDH.S374887","article-title":"Calcium channel blocker toxicity: a practical approach","volume":"15","author":"Alshaya","year":"2022","journal-title":"J Multidiscip Healthc"},{"key":"2024021707135134000_zuad138-B20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.emc.2007.02.001","article-title":"Management of beta-adrenergic blocker and calcium channel antagonist toxicity","volume":"25","author":"Kerns","year":"2007","journal-title":"Emerg Med Clin North Am"},{"key":"2024021707135134000_zuad138-B21","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1097\/00003246-199507000-00016","article-title":"Beneficial myocardial metabolic effects of insulin during verapamil toxicity in the anesthetized canine","volume":"23","author":"Kline","year":"1995","journal-title":"Crit Care Med"},{"key":"2024021707135134000_zuad138-B22","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/00005344-199605000-00015","article-title":"Myocardial metabolism during graded intraportal verapamil infusion in awake dogs","volume":"27","author":"Kline","year":"1996","journal-title":"J Cardiovasc Pharmacol"},{"key":"2024021707135134000_zuad138-B23","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00139709-200423040-00002","article-title":"The role of insulin and glucose (hyperinsulinaemia\/euglycaemia) therapy in acute calcium channel antagonist and beta-blocker poisoning","volume":"23","author":"M\u00e9garbane","year":"2004","journal-title":"Toxicol Rev"},{"key":"2024021707135134000_zuad138-B24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3109\/15563650.2013.770152","article-title":"A blinded, randomized, controlled trial of three doses of high-dose insulin in poison-induced cardiogenic shock","volume":"51","author":"Cole","year":"2013","journal-title":"Clin Toxicol"},{"key":"2024021707135134000_zuad138-B25","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.ajem.2018.02.004","article-title":"High dose insulin for beta-blocker and calcium channel-blocker poisoning","volume":"36","author":"Cole","year":"2018","journal-title":"Am J Emerg Med"},{"key":"2024021707135134000_zuad138-B26","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/15563650.2017.1391391","article-title":"The safety of high-dose insulin euglycaemia therapy in toxin-induced cardiac toxicity","volume":"56","author":"Page","year":"2018","journal-title":"Clin Toxicol"},{"key":"2024021707135134000_zuad138-B27","doi-asserted-by":"crossref","first-page":"A242","DOI":"10.1016\/j.chest.2017.08.268","article-title":"The use of high dose insulin therapy in a case of diltiazem (calcium channel blocker) poisoning","volume":"152","author":"Wajahat","year":"2017","journal-title":"CHEST"},{"key":"2024021707135134000_zuad138-B28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1757-7241-18-51","article-title":"Intravenous lipid emulsion in clinical toxicology","volume":"18","author":"Rothschild","year":"2010","journal-title":"Scand J Trauma Resusc Emerg Med"},{"key":"2024021707135134000_zuad138-B29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s13181-013-0356-1","article-title":"Complications following antidotal use of intravenous lipid emulsion therapy","volume":"10","author":"Levine","year":"2014","journal-title":"J Med Toxicol"},{"key":"2024021707135134000_zuad138-B30","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s13181-016-0550-z","article-title":"ACMT position statement: guidance for the use of intravenous lipid emulsion","volume":"13","author":"American College of Medical Toxicology","year":"2017","journal-title":"J Med Toxicol"},{"key":"2024021707135134000_zuad138-B31","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.resuscitation.2012.03.028","article-title":"A comparison of survival with and without extracorporeal life support treatment for severe poisoning due to drug intoxication","volume":"83","author":"Masson","year":"2012","journal-title":"Resuscitation"},{"key":"2024021707135134000_zuad138-B32","first-page":"e31158","article-title":"Methylene blue in refractory shock","volume":"14","author":"Chalise","year":"2022","journal-title":"Cureus"},{"key":"2024021707135134000_zuad138-B33","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0196-0644(82)80502-7","article-title":"Methemoglobinemia","volume":"11","author":"Curry","year":"1982","journal-title":"Ann Emerg Med"},{"key":"2024021707135134000_zuad138-B34","doi-asserted-by":"crossref","first-page":"462","DOI":"10.4103\/aca.ACA_88_17","article-title":"The Use of Intravenous Hydroxocobalamin as a Rescue in Methylene Blue-resistant Vasoplegic Syndrome in Cardiac Surgery","volume":"20","author":"Cai","year":"2017","journal-title":"Ann Card Anaesth"},{"key":"2024021707135134000_zuad138-B35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s13054-021-03585-7","article-title":"Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup","volume":"25","author":"Bouchard","year":"2021","journal-title":"Crit Care"},{"key":"2024021707135134000_zuad138-B36","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/15563650.2020.1870123","article-title":"Complex management of AV nodal agent toxicity in patients with cardiac devices: massive calcium channel antagonist overdose in a patient with a permanent pacemaker","volume":"59","author":"Wong","year":"2021","journal-title":"Clin Toxicol"},{"key":"2024021707135134000_zuad138-B37"},{"key":"2024021707135134000_zuad138-B38"},{"key":"2024021707135134000_zuad138-B39"}],"container-title":["European Heart Journal: Acute Cardiovascular Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjacc\/advance-article-pdf\/doi\/10.1093\/ehjacc\/zuad138\/53711514\/zuad138.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjacc\/article-pdf\/13\/2\/247\/56688360\/zuad138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjacc\/article-pdf\/13\/2\/247\/56688360\/zuad138.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T07:14:19Z","timestamp":1708154059000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjacc\/article\/13\/2\/247\/7425540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,17]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,11,17]]},"published-print":{"date-parts":[[2024,2,16]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjacc\/zuad138","relation":{},"ISSN":["2048-8726","2048-8734"],"issn-type":[{"value":"2048-8726","type":"print"},{"value":"2048-8734","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2023,11,17]]}}}